{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T14:52:50Z","timestamp":1794581570705,"version":"4.9.1"},"reference-count":12,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"1","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>\n                    <jats:italic>Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in<\/jats:italic>\n                    JCO\n                    <jats:italic>or elsewhere, for which the primary end point has already been reported<\/jats:italic>\n                    .\n                  <\/jats:p>\n                  <jats:p>CheckMate 274 is a phase III, randomized, double-blind trial of adjuvant nivolumab versus placebo for muscle-invasive urothelial carcinoma (MIUC) at high risk of recurrence after radical resection. The primary end points of disease-free survival (DFS) in intent-to-treat (ITT) and tumor PD-L1 expression \u22651% populations were met. We report results at an extended median follow-up of 36.1 months in the ITT population. In addition, we report interim overall survival (OS) data for the first time and an exploratory analysis among patients with bladder primary tumors (muscle-invasive bladder cancer [MIBC]). Consistent DFS benefit with nivolumab versus placebo was observed in both the ITT (hazard ratio [HR], 0.71 [95% CI, 0.58 to 0.86]) and PD-L1 \u22651% (HR, 0.52 [95% CI, 0.37 to 0.72]) patients. The HR for OS with nivolumab versus placebo was 0.76 (95% CI, 0.61 to 0.96) in the ITT population and 0.56 (95% CI, 0.36 to 0.86) in the PD-L1 \u22651 population. Continuous benefit in nonurothelial tract recurrence-free survival and distant metastasis-free survival was also observed in both patient populations. The exploratory analysis of patients with MIBC also showed continued efficacy benefits, irrespective of PD-L1 status. No new safety signals were reported. Overall, these results further support adjuvant nivolumab as a standard of care for high-risk MIUC after radical resection.<\/jats:p>","DOI":"10.1200\/jco.24.00340","type":"journal-article","created":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T15:59:08Z","timestamp":1728662348000},"page":"15-21","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":128,"title":["Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274"],"prefix":"10.1200","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct02632409","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7655-9378","authenticated-orcid":true,"given":"Matthew D.","family":"Galsky","sequence":"first","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes Alfred","family":"Witjes","sequence":"additional","affiliation":[{"name":"Radboud University, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen E.","family":"Gschwend","sequence":"additional","affiliation":[{"name":"Technical University Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8965-8129","authenticated-orcid":true,"given":"Matthew I.","family":"Milowsky","sequence":"additional","affiliation":[{"name":"University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2645-6391","authenticated-orcid":true,"given":"Michael","family":"Schenker","sequence":"additional","affiliation":[{"name":"Sf. Nectarie Oncology Center, Craiova, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bego\u00f1a P.","family":"Valderrama","sequence":"additional","affiliation":[{"name":"Hospital Universitario Virgen del Roc\u00edo, Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Tomita","sequence":"additional","affiliation":[{"name":"Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aristotelis","family":"Bamias","sequence":"additional","affiliation":[{"name":"National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Lebret","sequence":"additional","affiliation":[{"name":"H\u00f4pital Foch, Paris-Saclay University UVSQ, Versailles, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6627-6179","authenticated-orcid":true,"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[{"name":"Medical University of Vienna, Vienna General Hospital, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5084-9326","authenticated-orcid":true,"given":"Se Hoon","family":"Park","sequence":"additional","affiliation":[{"name":"Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3923-6136","authenticated-orcid":true,"given":"Mads","family":"Agerbaek","sequence":"additional","affiliation":[{"name":"Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Jha","sequence":"additional","affiliation":[{"name":"M Health Fairview Clinics and Surgery Center, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Stenner","sequence":"additional","affiliation":[{"name":"University Hospital Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4974-3780","authenticated-orcid":true,"given":"Dingwei","family":"Ye","sequence":"additional","affiliation":[{"name":"Fudan University Shanghai Cancer Center, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Giudici","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3900-6349","authenticated-orcid":true,"given":"Santanu","family":"Dutta","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Askelson","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Nasroulah","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Zhang","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne","family":"Brophy","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4001-7088","authenticated-orcid":true,"given":"Dean F.","family":"Bajorin","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_9_2_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562872211029779"},{"key":"e_1_3_9_3_2","first-page":"246","article-title":"Disease-free survival at 2 and 3 years is a significant early surrogate marker predicting the 5-year overall survival in patients treated with radical cystectomy for urothelial carcinoma of the bladder: External evaluation and validation in a cohort of Korean patients","volume":"5","author":"Kim HS","year":"2015","unstructured":"Kim HS, Jeong CW, Kwak C, et al: Disease-free survival at 2 and 3 years is a significant early surrogate marker predicting the 5-year overall survival in patients treated with radical cystectomy for urothelial carcinoma of the bladder: External evaluation and validation in a cohort of Korean patients. Front Oncol 5:246, 2015","journal-title":"Front Oncol"},{"key":"e_1_3_9_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103683"},{"key":"e_1_3_9_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034442"},{"key":"e_1_3_9_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/17562872221134389"},{"key":"e_1_3_9_7_2","unstructured":"Galsky MD Witjes JA Gschwend JE et al: Disease-free survival with longer follow-up from the phase 3 CheckMate 274 trial of adjuvant nivolumab in patients who underwent surgery for high-risk muscle-invasive urothelial carcinoma. Presented at the Society of Urologic Oncology 22nd Annual Meeting Virtual December 1-3 2021 (abst 1514)"},{"key":"e_1_3_9_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.4585"},{"key":"e_1_3_9_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2012.02.187"},{"key":"e_1_3_9_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.09.110"},{"key":"e_1_3_9_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.1824"},{"key":"e_1_3_9_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.01.016"},{"key":"e_1_3_9_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.4_suppl.LBA531"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.24.00340","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T17:59:56Z","timestamp":1734717596000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.24.00340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1200\/JCO.24.00340"],"URL":"https:\/\/doi.org\/10.1200\/jco.24.00340","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2024-02-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-01","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}